BioNTech Delivers First Patient Dose In Herpes Vaccine Clinical Trial

BioNTech has finally dosed the first patient with its Herpes Vaccine (BNT163) in a candidate clinical trial. According to the German Vaccine maker, “The vaccine is designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study.”
Read more: https://thetechwires.com/news/biontech-delivers-first-patient-dose-in-herpes-vaccine-clinical-trial/?source=Snapzu